KR100292396B1 - - Google Patents

Info

Publication number
KR100292396B1
KR100292396B1 KR19940703608A KR19940703608A KR100292396B1 KR 100292396 B1 KR100292396 B1 KR 100292396B1 KR 19940703608 A KR19940703608 A KR 19940703608A KR 19940703608 A KR19940703608 A KR 19940703608A KR 100292396 B1 KR100292396 B1 KR 100292396B1
Authority
KR
South Korea
Prior art keywords
angiotensin
treating
development
preventing
conditions associated
Prior art date
Application number
KR19940703608A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929208116A external-priority patent/GB9208116D0/en
Priority claimed from GB929211289A external-priority patent/GB9211289D0/en
Application filed filed Critical
Application granted granted Critical
Publication of KR100292396B1 publication Critical patent/KR100292396B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR19940703608A 1992-04-13 1994-10-11 KR100292396B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB929208116A GB9208116D0 (en) 1992-04-13 1992-04-13 Therapeutic agents
GB929211289A GB9211289D0 (en) 1992-05-28 1992-05-28 Heterocyclic therapeutic agents
PCT/GB1993/000732 WO1993020816A1 (en) 1992-04-13 1993-04-07 Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy

Publications (1)

Publication Number Publication Date
KR100292396B1 true KR100292396B1 (ko) 2001-09-17

Family

ID=26300705

Family Applications (1)

Application Number Title Priority Date Filing Date
KR19940703608A KR100292396B1 (ko) 1992-04-13 1994-10-11

Country Status (14)

Country Link
EP (2) EP0636027B1 (ko)
JP (1) JPH07505646A (ko)
KR (1) KR100292396B1 (ko)
AT (1) ATE181830T1 (ko)
AU (1) AU675935B2 (ko)
CA (1) CA2132544C (ko)
DE (1) DE69325574T2 (ko)
DK (1) DK0636027T3 (ko)
ES (1) ES2135472T3 (ko)
GR (1) GR3031261T3 (ko)
HU (1) HUT71331A (ko)
NO (1) NO313935B1 (ko)
NZ (1) NZ251741A (ko)
WO (1) WO1993020816A1 (ko)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY119312A (en) * 1995-10-06 2005-05-31 Novartis Ag At 1-receptor antagonists for preventing and treating postischemic renal failure and for protecting ischemic kidneys
ATE230263T1 (de) 1996-02-29 2003-01-15 Novartis Erfind Verwalt Gmbh At1 rezeptor antagonist zur anregung von apoptosis
ATE220333T1 (de) * 1996-04-05 2002-07-15 Takeda Chemical Industries Ltd Pharmazeutische kombination enthaltend einen wirkstoff mit angiotensin-ii antagonistischer aktivität und einen wirkstoff der die insulin- sensitivität erhöht
US6465502B1 (en) 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
TR200805275T2 (tr) 1998-12-23 2008-09-22 Novartis Ag AT-1 veya AT-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için AT-1 reseptör antagonisti veya AT-2 reseptör modülatörünün kullanımı@
CN101011390A (zh) 1999-01-26 2007-08-08 诺瓦提斯公司 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用
GB0001662D0 (en) 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
US6211217B1 (en) 1999-03-16 2001-04-03 Novartis Ag Method for reducing pericardial fibrosis and adhesion formation
DE10335027A1 (de) 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
JP4966202B2 (ja) 2004-12-24 2012-07-04 スピニフェクス ファーマシューティカルズ ピーティーワイ リミテッド 治療または予防のための方法
US20130131007A1 (en) 2005-09-07 2013-05-23 Bebaas, Inc. Vitamin b12 compositions
US8551950B2 (en) 2006-03-20 2013-10-08 Spinifex Pharmaceuticals Pty Ltd Method of treatment or prophylaxis of inflammatory pain
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
CN102821765A (zh) * 2010-01-19 2012-12-12 西芬克斯医药有限公司 改良神经传导速度的方法和组合物
KR20200026975A (ko) 2017-07-07 2020-03-11 베링거잉겔하임베트메디카게엠베하 고양이에서 전신 질환의 예방 또는 치료를 위한 안지오텐신 ii 수용체 길항제

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991014367A1 (en) * 1990-03-20 1991-10-03 E.I. Du Pont De Nemours And Company Treatment of central nervous system disorders with imidazole angiotensin-ii receptor antagonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0412848B1 (en) * 1989-08-11 1995-01-18 Zeneca Limited Quinoline derivatives, process for their preparation and their use as medicaments
GB8927277D0 (en) * 1989-12-01 1990-01-31 Glaxo Group Ltd Chemical compounds
US5049565A (en) * 1990-12-07 1991-09-17 Merck & Co., Inc. Microbial transformation process for preparing anti-hypertensive products
GB9027211D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
GB9027210D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
AU1625192A (en) * 1991-05-31 1992-12-03 Zeneca Limited Heterocyclic derivatives
ATE152718T1 (de) * 1991-08-15 1997-05-15 Ciba Geigy Ag N-acyl-n-heterocyclyl- oder naphthylalkyl- aminosäuren als angiotensin ii antagonisten

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991014367A1 (en) * 1990-03-20 1991-10-03 E.I. Du Pont De Nemours And Company Treatment of central nervous system disorders with imidazole angiotensin-ii receptor antagonists

Also Published As

Publication number Publication date
GR3031261T3 (en) 1999-12-31
WO1993020816A1 (en) 1993-10-28
EP0636027B1 (en) 1999-07-07
DE69325574T2 (de) 2000-03-16
EP0872235A1 (en) 1998-10-21
CA2132544A1 (en) 1993-10-28
EP0636027A1 (en) 1995-02-01
JPH07505646A (ja) 1995-06-22
DK0636027T3 (da) 2000-01-31
NO943846L (no) 1994-10-12
DE69325574D1 (de) 1999-08-12
HUT71331A (en) 1995-11-28
ATE181830T1 (de) 1999-07-15
NO943846D0 (no) 1994-10-12
ES2135472T3 (es) 1999-11-01
CA2132544C (en) 2005-10-18
NO313935B1 (no) 2002-12-30
HU9402932D0 (en) 1995-02-28
AU3958993A (en) 1993-11-18
NZ251741A (en) 1997-06-24
AU675935B2 (en) 1997-02-27

Similar Documents

Publication Publication Date Title
KR100292396B1 (ko)
AU8188987A (en) Improved metal complex-containing pharmaceutical agents
BG103740A (en) Phytostyrene composition for the prevention of the alzheimer's disease
ES2058346T3 (es) Compuestos piperidinilicos 1,4-disustituidos.
SE8802570L (sv) Ny anvaendning av 5ht-3-antagonister
IT1246983B (it) L-2'-desossiuridine e composizioni farmaceutiche che le contengono.
FI950697A (fi) IL-4:n ja/tai IL-10:n uudet käytöt ja vasta-aineet niitä vastaan
ES2164684T3 (es) Uso de antagonistas de taquiquininas en el tratamiento de emesis.
FI972308A0 (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
BG105256A (en) Muscarinic agonists and antagonists
BG103968A (en) Pharmaceutical antiviral composition containing glycirricinic acid and at least one protein with antiviral activity
ES2080736T3 (es) Uso de 2,3,4,5-tetrahidro-1h-3-benzazepinas en el tratamiento de trastornos neurologicos.
BG101849A (en) Bicyclic tachyquinine antagonists, their preparation and use in pharmaceutical compositions
ES2150418T3 (es) Composiciones farmaceuticas que comprenden calcitonina.
ES2056876T3 (es) Compuestos piperidinilicos 1,4-disustituidos.
ATE195055T1 (de) Insektizide zusammensetzung die diatomeenerde und siliziumdioxid enthalten
FI923751A0 (fi) Hexahydrobenso/f/kinolinoner.
MX9302142A (es) Uso de 3r- y 3r,s-difenilmetoxi-1-(3,4-metileno-dioxifenetil)-piperidina y composicion que la contienen.
ES2090170T3 (es) Agente de recubrimiento espermicida.
GR3018795T3 (en) Emulsion-free emulsion polymers in sustained-release pharmaceutical compositions and their production
DE3869232D1 (de) Abkoemmlinge von bornan-3-spiro-l'-cyclopentan und diese enthaltende riechstoffzusammensetzungen.
ATE82855T1 (de) 2',3'-dideoxypurinnucleosid/purinnucleosidphosphorylase-inhibitor kombinationstherapie und zusammensetzungen dafuer.

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
J201 Request for trial against refusal decision
AMND Amendment
B701 Decision to grant
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20100122

Year of fee payment: 10

LAPS Lapse due to unpaid annual fee